Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia's Sigma Unlikely To Be Saved By iNova Investors

This article was originally published in PharmAsia News

Executive Summary

Reports predicting Australia's financially troubled Sigma Pharmaceuticals might be bought and saved are being dashed by closer looks at possible suitors

You may also be interested in...



French Experts Call For Mass Vitamin D Supplementation To Fight COVID-19

With around half the French population vitamin D deficient, a group of medical experts say mass supplementation is a low cost and low risk intervention which could save lives and curb the spread of COVID-19.

Rising From The Ashes Of 2020: ‘We Must Not Waste The Learning,’ Says Dame Sally

UK special envoy on antimicrobial resistance Professor Dame Sally Davies, who is also the former chief medical officer for England, talks to In Vivo about the challenges of 2020, the importance of a strong working relationship between the public and private sectors, and reaching a turning point on AMR.

Options, Expertise And Risk Tolerance Needed For Successful Value-Based Contracts

Biohaven Pharmaceuticals developed six different value-based contracting options to support the launch of acute migraine therapy, Nurtec ODT. Despite contract complexity and lingering regulatory risk, payers are aggressively pursuing value-based contracts, leading even small biopharmas to invest in strong health economics capabilities.

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel